Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.
Parks
Mary
M
Division of Metabolism and Endocrinology Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Rosebraugh
Curtis
C
D000818:Animals; D015415:Biomarkers / Q000097:blood; D002116:Calcitonin / Q000097:blood; D002318:Cardiovascular Diseases; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D017277:Drug Approval; D004359:Drug Therapy, Combination; D052216:Glucagon-Like Peptide 1 / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069450:Liraglutide; D010195:Pancreatitis / Q000139:chemically induced; D012307:Risk Factors; D012377:Rodentia; D013964:Thyroid Neoplasms / Q000139:chemically induced*; D014481:United States; D014486:United States Food and Drug Administration
D015415:Biomarkers; D007004:Hypoglycemic Agents; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D002116:Calcitonin